Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Falkensee – page 133

1 865 clinical trials in Falkensee, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Falkensee at a glance
1 865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 865 trials in Falkensee

Open in trial search

Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Study on Afatinib and Osimertinib for Patients with EGFR-Mutated, T790M Negative Non-Squamous Non-Small Cell Lung Cancer in First-Line Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AIO-Studien gGmbH

Colitis ulcerative

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Vaginal infection

Not recruiting

Study on the Effectiveness and Safety of BGY-1601-VT for Women with Acute Vaginal Infections, Including Bacterial Vaginosis and Yeast Infections

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Lactobacillus rhamnosus, strain LCR35, live
  • Sponsor:Nexbiome Therapeutics

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Study on R3R01 for Patients with Alport Syndrome and Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:R3R01
  • Sponsor:River 3 Renal Corp.

Study on Health, Activity, and Joint Outcomes in Patients Aged 13-69 with Severe or Moderate Hemophilia A Using Emicizumab

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dimethyl Fumarate
  • Sponsor:Novartis Pharma AG

Neoplasm malignant+1

Not recruiting

Study of Entrectinib for Patients with Advanced or Metastatic Solid Tumors with Specific Gene Changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Entrectinib
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Falkensee

What the registry says about research in the country

01 Metabolic Disorders

Innovative research focusing on Type 2 Diabetes Mellitus management and glycemic control, evaluating new therapeutic approaches including novel compounds and established treatments.

  • Glycemic Control Studies
  • Cardiovascular Outcomes
  • Diabetes Management

Multiple trials are investigating both single and combination therapies for improving patient outcomes.

02 Cardiovascular Health

Comprehensive studies addressing atherosclerotic cardiovascular disease and cholesterol management, examining innovative treatments for reducing major adverse cardiovascular events.

  • Lipid Management
  • Cardiovascular Risk Reduction
  • Arterial Health

Research focuses on comparing effectiveness of different therapeutic approaches for cholesterol control.

03 Metabolic and Renal Health

Groundbreaking research combining treatments for chronic kidney disease and metabolic conditions, including studies on weight management and obesity-related complications.

  • Weight Management
  • Kidney Disease Progression
  • Blood Pressure Control

Trials evaluate combination therapies targeting multiple health conditions simultaneously.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.